AR042002A1 - Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. - Google Patents

Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central.

Info

Publication number
AR042002A1
AR042002A1 ARP030104100A ARP030104100A AR042002A1 AR 042002 A1 AR042002 A1 AR 042002A1 AR P030104100 A ARP030104100 A AR P030104100A AR P030104100 A ARP030104100 A AR P030104100A AR 042002 A1 AR042002 A1 AR 042002A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
nervous system
central nervous
benzoxazinonas
Prior art date
Application number
ARP030104100A
Other languages
English (en)
Inventor
Hans Maag
Meng Sui
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR042002A1 publication Critical patent/AR042002A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D291/00Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto de fórmula (1). También se proporciona métodos para la preparación, composiciones que lo comprenden, y métodos para el uso de compuestos para enfermedades del sistema nervioso central. Reivindicación 1: Un compuesto de la fórmula (1) o una sal o pro-fármaco aceptable farmacéuticamente del mismo, en donde: Y es C o S; m es 1 cuando Y es C y m es 2 cuando Y es S; n es 1 o 2; p es de 0 a 3; q es de 1 a 3; Z es -(CRaRb)x-, o -SO2-, donde cada Ra y Rb son H o alquilo independientemente; r es de 0 a 2; X es CH o N; cada R1 es independientemente halógeno, alquilo, haloalquilo, heteroalquilo, alcoxilo, ciano, -S(O)s-Rc, -C(=O)-NRcRd, -SO2-NRcRd, -N(Rc)-C(=O)-Rd, o -C(=O)-Rc, donde cada Rc y Rd es independientemente H o alquilo; s es de 0 a 2; R2 es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; cada uno de R3 y R4 es independientemente H o alquilo, o R3 y R4 junto con sus carbonos compartidos pueden formar un anillo cicloalquilo de 3 a 6 miembros; y cada uno de R5, R6, R7. R8, y R9 son independientemente H o alquilo, o uno de R5 y R6 junto con uno de R7, R8, y R9 y los átomos de en medio pueden formar un anillo de 5 a 7 miembros.
ARP030104100A 2002-11-08 2003-11-07 Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. AR042002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42494602P 2002-11-08 2002-11-08

Publications (1)

Publication Number Publication Date
AR042002A1 true AR042002A1 (es) 2005-06-08

Family

ID=32312902

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104100A AR042002A1 (es) 2002-11-08 2003-11-07 Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central.

Country Status (28)

Country Link
US (1) US7141562B2 (es)
EP (1) EP1562918B1 (es)
JP (1) JP4401297B2 (es)
KR (1) KR100683361B1 (es)
CN (1) CN100390157C (es)
AR (1) AR042002A1 (es)
AT (1) ATE384054T1 (es)
AU (1) AU2003293653B2 (es)
BR (1) BR0315302A (es)
CA (1) CA2505334A1 (es)
DE (1) DE60318733T2 (es)
DK (1) DK1562918T3 (es)
ES (1) ES2298609T3 (es)
GT (1) GT200300241A (es)
HR (1) HRP20050390A2 (es)
IL (1) IL168343A (es)
MX (1) MXPA05004758A (es)
MY (1) MY136824A (es)
NO (1) NO20052074L (es)
NZ (1) NZ539508A (es)
PA (1) PA8587501A1 (es)
PE (1) PE20040828A1 (es)
PL (1) PL377770A1 (es)
PT (1) PT1562918E (es)
RU (1) RU2328490C2 (es)
TW (1) TWI285639B (es)
WO (1) WO2004041792A1 (es)
ZA (1) ZA200503248B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322539B2 (en) 2001-07-20 2007-09-27 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
WO2005058847A1 (en) 2003-12-09 2005-06-30 F. Hoffmann-La Roche Ag Benzoxazine derivatives and uses thereof
WO2006037482A2 (en) * 2004-09-30 2006-04-13 F. Hoffmann-La Roche Ag Compositions and methods for treating cognitive disorders
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
CN101263136A (zh) 2005-07-13 2008-09-10 弗·哈夫曼-拉罗切有限公司 作为5-ht6、5-ht24的苯并咪唑衍生物
WO2007032572A1 (en) * 2005-09-15 2007-03-22 Korea Reserach Institute Of Chemical Technology N-substituted-1h-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same
TWI385161B (zh) * 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
PT2040755E (pt) * 2006-06-23 2011-07-08 Esteve Labor Dr Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
ITMI20131782A1 (it) * 2013-10-25 2015-04-26 Dipharma Francis Srl Procedimento per la preparazione di un agonista della trombopoietina
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
EP3322415A4 (en) 2015-07-15 2019-03-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
RU2624978C2 (ru) * 2015-07-27 2017-07-11 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения умеренного когнитивного снижения
SMT202100305T1 (it) * 2017-08-07 2021-07-12 Suven Life Sciences Ltd Composti di fluoropiperidina come antagonisti dei recettori 5–ht6 puri
CN111559990B (zh) * 2020-05-29 2021-03-09 四川大学华西医院 一种小分子噁噻嗪类衍生物及其应用
CN112047898A (zh) * 2020-10-14 2020-12-08 兰州大学 一种苯并[c][1,2]噁嗪骨架类新化合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU784769A3 (ru) * 1977-03-17 1980-11-30 Шел Интернэшнл Рисерч Маатсхаппии Б.В. (Фирма) Способ получени бензоксазинкарбоксамидов
ATE81975T1 (de) 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
AU605304B2 (en) * 1987-06-22 1991-01-10 Nihon Tokushu Nayaku Seizo K.K. Benzo-fused cyclic compounds
FR2667068B1 (fr) * 1990-09-26 1994-09-09 Adir Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
US6225312B1 (en) 1996-03-29 2001-05-01 Duphar International Research B.V. Piperazine and piperidine compounds
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
ES2244469T3 (es) * 1999-08-23 2005-12-16 Solvay Pharmaceuticals B.V. Fenilpiperazinas como inhibidores de la recaptacion de serotonina.
US20020013314A1 (en) 2000-02-01 2002-01-31 Bing-Yan Zhu 3,4-dihydro-2H-benzo[1,4]oxazine inhibitors of factor Xa
US20020019394A1 (en) 2000-03-24 2002-02-14 Wenhao Li Bicyclic sulfonyl amino inhibitors of factor Xa
DE10031391A1 (de) 2000-07-03 2002-02-07 Knoll Ag Bicyclische Verbindungen und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
CN1478092A (zh) * 2000-10-26 2004-02-25 ʷ 苯并噁嗪酮衍生物及其制备和应用
MXPA04001250A (es) * 2001-08-10 2004-05-27 Hoffmann La Roche Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6).
CA2485136C (en) * 2002-05-13 2011-12-20 F. Hoffmann-La Roche Ag Benzoxazine derivatives as 5-ht6 modulators and uses thereof

Also Published As

Publication number Publication date
PE20040828A1 (es) 2004-11-25
NO20052074L (no) 2005-06-01
RU2005117965A (ru) 2006-01-27
PL377770A1 (pl) 2006-02-20
TW200418846A (en) 2004-10-01
AU2003293653B2 (en) 2009-05-14
DE60318733T2 (de) 2009-01-15
KR100683361B1 (ko) 2007-02-15
GT200300241A (es) 2004-06-03
EP1562918A1 (en) 2005-08-17
EP1562918B1 (en) 2008-01-16
ATE384054T1 (de) 2008-02-15
JP2006514615A (ja) 2006-05-11
US7141562B2 (en) 2006-11-28
PT1562918E (pt) 2008-03-12
BR0315302A (pt) 2005-08-23
ES2298609T3 (es) 2008-05-16
US20040092512A1 (en) 2004-05-13
JP4401297B2 (ja) 2010-01-20
DK1562918T3 (da) 2008-05-05
AU2003293653A1 (en) 2004-06-07
CA2505334A1 (en) 2004-05-21
IL168343A (en) 2010-05-31
CN100390157C (zh) 2008-05-28
WO2004041792A1 (en) 2004-05-21
KR20050072479A (ko) 2005-07-11
NZ539508A (en) 2007-05-31
MXPA05004758A (es) 2005-08-02
ZA200503248B (en) 2006-02-22
DE60318733D1 (de) 2008-03-06
PA8587501A1 (es) 2004-05-26
RU2328490C2 (ru) 2008-07-10
MY136824A (en) 2008-11-28
TWI285639B (en) 2007-08-21
HRP20050390A2 (en) 2006-12-31
CN1723205A (zh) 2006-01-18

Similar Documents

Publication Publication Date Title
AR042002A1 (es) Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central.
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
AR043436A1 (es) Tetrahidroisoquinolinas sustituidas para uso como moduladores 5-ht6
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR027406A1 (es) Moduladores de receptores canabinoides, sus procesos de preparacion y uso de los moduladores de receptores canabinoides para el tratamiento de enfermedadesrespiratorias y no respiratorias.
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
CO5261616A1 (es) Inhibidores no peptidicos de la union celular dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
ATE369855T1 (de) Modulatoren von peroxisome proliferator- aktivierten rezeptoren
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa
AR116474A1 (es) DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b
AR062405A1 (es) Derivados de isoindol
AR042155A1 (es) Aminoalcoxiindoles, composicion farmaceutica que los comprenden y usos
AR039651A1 (es) Derivados de isoquinolina

Legal Events

Date Code Title Description
FB Suspension of granting procedure